Insider Buying: Cerecor Inc (CERC) Director Purchases 42,159 Shares of Stock

Cerecor Inc (NASDAQ:CERC) Director Armistice Capital, Llc bought 42,159 shares of the firm’s stock in a transaction that occurred on Monday, May 21st. The shares were purchased at an average cost of $3.77 per share, for a total transaction of $158,939.43. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Armistice Capital, Llc also recently made the following trade(s):

  • On Wednesday, May 23rd, Armistice Capital, Llc bought 300 shares of Cerecor stock. The shares were purchased at an average cost of $3.85 per share, for a total transaction of $1,155.00.
  • On Tuesday, May 15th, Armistice Capital, Llc bought 92,700 shares of Cerecor stock. The shares were purchased at an average cost of $3.51 per share, for a total transaction of $325,377.00.
  • On Monday, April 23rd, Armistice Capital, Llc bought 6,189 shares of Cerecor stock. The shares were purchased at an average cost of $4.17 per share, for a total transaction of $25,808.13.
  • On Friday, April 20th, Armistice Capital, Llc bought 600 shares of Cerecor stock. The shares were purchased at an average cost of $3.59 per share, for a total transaction of $2,154.00.
  • On Wednesday, April 18th, Armistice Capital, Llc bought 81,544 shares of Cerecor stock. The shares were purchased at an average cost of $3.41 per share, for a total transaction of $278,065.04.
  • On Monday, April 16th, Armistice Capital, Llc bought 41,096 shares of Cerecor stock. The shares were purchased at an average cost of $3.36 per share, for a total transaction of $138,082.56.

Cerecor traded down $0.02, reaching $3.84, during midday trading on Wednesday, Marketbeat reports. 70,000 shares of the stock were exchanged, compared to its average volume of 287,446. The company has a current ratio of 0.91, a quick ratio of 0.67 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $117.68 million, a PE ratio of 9.14 and a beta of 1.30. Cerecor Inc has a 52 week low of $0.42 and a 52 week high of $5.74.

Cerecor (NASDAQ:CERC) last posted its earnings results on Friday, May 11th. The company reported ($0.07) earnings per share for the quarter. The firm had revenue of $4.48 million for the quarter. Cerecor had a return on equity of 59.50% and a net margin of 31.17%. research analysts forecast that Cerecor Inc will post -0.39 earnings per share for the current year.

A number of institutional investors have recently bought and sold shares of CERC. Virtu Financial LLC bought a new stake in Cerecor during the 4th quarter worth approximately $560,000. O Shaughnessy Asset Management LLC bought a new position in shares of Cerecor in the 1st quarter worth $315,000. Acadian Asset Management LLC bought a new position in shares of Cerecor in the 4th quarter worth $194,000. Armistice Capital LLC increased its holdings in shares of Cerecor by 0.3% in the 4th quarter. Armistice Capital LLC now owns 16,050,000 shares of the company’s stock worth $51,360,000 after buying an additional 50,000 shares during the last quarter. Finally, Northern Trust Corp increased its holdings in shares of Cerecor by 182.0% in the 1st quarter. Northern Trust Corp now owns 31,506 shares of the company’s stock worth $135,000 after buying an additional 20,333 shares during the last quarter. 53.71% of the stock is currently owned by institutional investors and hedge funds.

Cerecor Company Profile

Cerecor Inc, a clinical-stage biopharmaceutical company, develops drugs to treat patients with neurological and psychiatric disorders. It develops CERC-501, which has completed Phase II clinical trial for the adjunctive treatment of major depressive disorder (MDD), as well as to treat substance use disorders; CERC-301 that has completed Phase II clinical trial for the adjunctive treatment of patients with MDD; and CERC-406 that is in preclinical stage to treat residual cognitive impairment symptoms in patients with MDD.

Insider Buying and Selling by Quarter for Cerecor (NASDAQ:CERC)

Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply